secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001193125-26-086793
Event type: regulatory
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara and Pierre Fabre request FDA Type A meeting for tabelecleucel BLA resubmission
--------------------------------------------------------------------------------

- Pierre Fabre submitted Type A meeting request to FDA to address CRL issues for tabelecleucel (EBVALLO) BLA.
- Briefing book argues ALLELE study was adequate; includes updated efficacy data and European post-marketing data.
- FDA Complete Response Letter was issued January 9, 2026; meeting seeks path forward for EBV+ PTLD therapy.
- CEO Cokey Nguyen cites urgent unmet need expressed by PTLD community and physician advocates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526086793/0001193125-26-086793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526086793/d121575d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-086793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer